Citation Impact
Citing Papers
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
2007 Standout
DNA capture by a CRISPR-Cas9–guided adenine base editor
2020 StandoutScienceNobel
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
2005
In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter
2010 StandoutNobel
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
1999
Saccharomyces cerevisiae MutLα Is a Mismatch Repair Endonuclease
2007 StandoutNobel
Improved gRNA secondary structures allow editing of target sites resistant to CRISPR-Cas9 cleavage
2022 StandoutNobel
Multiplex nucleotide editing by high-fidelity Cas9 variants with improved efficiency in rice
2019
A Multiparameter Network Reveals Extensive Divergence between C. elegans bHLH Transcription Factors
2009
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
The DNA-damage response in human biology and disease
2009 StandoutNature
Distinct p53 genomic binding patterns in normal and cancer-derived human cells
2011
Demethylation of 3-Methylthymine in DNA by Bacterial and Human DNA Dioxygenases
2004 StandoutNobel
Transcriptional regulation by p53: one protein, many possibilities
2006
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
2020 StandoutNobel
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
2009 Standout
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
2006 Standout
p53 polymorphisms: cancer implications
2009
Molecular Biology of Barrett’s Adenocarcinoma
2001
Genetics, epigenetics and pharmaco‐(epi)genomics in angiogenesis
2008
A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response
2010 Standout
Prediction of the sequence-specific cleavage activity of Cas9 variants
2020
Structure–function–rescue: the diverse nature of common p53 cancer mutants
2007
When mutants gain new powers: news from the mutant p53 field
2009
Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents
2000 Standout
NmeCas9 is an intrinsically high-fidelity genome-editing platform
2018
Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning
2019
Single-nucleotide Polymorphisms in the p53 Signaling Pathway
2009
Functional Classification and Experimental Dissection of Long Noncoding RNAs
2018 Standout
Recent progress on the Ada response for inducible repair of DNA alkylation damage
2002 StandoutNobel
The Human Transcription Factors
2018 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Esophageal Cancer
2003 Standout
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
2018
Key role of the REC lobe during CRISPR–Cas9 activation by ‘sensing’, ‘regulating’, and ‘locking’ the catalytic HNH domain
2018 StandoutNobel
Structural Basis of DNA Recognition by p53 Tetramers
2006
Epigenetics in Cancer
2008 Standout
Transcription as a source of genome instability
2012
New approaches to understanding p53 gene tumor mutation spectra
1999
Minimal Methylated Substrate and Extended Substrate Range of Escherichia coli AlkB Protein, a 1-Methyladenine-DNA Dioxygenase
2003 StandoutNobel
<i>TP53</i> Status and Response to Chemotherapy in Breast Cancer
2008
Blinded by the Light: The Growing Complexity of p53
2009 Standout
DNA Damage, Aging, and Cancer
2009 Standout
Highly Parallel Profiling of Cas9 Variant Specificity
2020
Mutational spectra of human cancer
2009
Comparative Binding of p53 to its Promoter and DNA Recognition Elements
2005
Mutational Analysis of the p53 Core Domain L1 Loop
2006
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication
2006
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
2020 Standout
Deciphering Off-Target Effects in CRISPR-Cas9 through Accelerated Molecular Dynamics
2019 StandoutNobel
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatches
2020 StandoutNobel
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
Evolution of the mammalian transcription factor binding repertoire via transposable elements
2008
Genome-wide profiling of adenine base editor specificity by EndoV-seq
2019
p53 and Human Cancer: The First Ten Thousand Mutations
1999
Hallmarks of Cellular Senescence
2018 Standout
Increasing the specificity of CRISPR systems with engineered RNA secondary structures
2019
hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes
2007
B cells under influence: transformation of B cells by Epstein–Barr virus
2003
A thermostable Cas9 with increased lifetime in human plasma
2017 StandoutNobel
The next generation of CRISPR–Cas technologies and applications
2019
Improving Plant Genome Editing with High-Fidelity xCas9 and Non-canonical PAM-Targeting Cas9-NG
2019
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
2007
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature
2014
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
2016 StandoutNobel
Mouse models for generating P53 gene mutation spectra
2002
Directed evolution of CRISPR-Cas9 to increase its specificity
2018
Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
2005
Characterization of genome-wide p53-binding sites upon stress response
2008
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
2014 Standout
p53 alterations in human cancer: more questions than answers
2007
A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing
2018
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
The first 30 years of p53: growing ever more complex
2009 Standout
The p53 tumor suppressor participates in multiple cell cycle checkpoints
2006
The Delitto Perfetto Approach to In Vivo Site‐Directed Mutagenesis and Chromosome Rearrangements with Synthetic Oligonucleotides in Yeast
2006
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
2009 StandoutNatureNobel
High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells
2020
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Mechanisms associated with mitochondrial-generated reactive oxygen species in cancerThis article is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.
2010
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements
2007 StandoutNobel
Differential Recognition of Response Elements Determines Target Gene Specificity forp53 and p63
2005
Pillar[5]arene as a Co-Factor in Templating Rotaxane Formation
2013 StandoutNobel
Cucurbituril-Based Molecular Recognition
2015 Standout
Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
2012
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate
2006
Noncoding RNAs in Vascular Diseases
2020
p53-Induced DNA Bending: The Interplay between p53−DNA and p53−p53 Interactions
2008
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene
2004
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
2006
Transcriptional control of human p53-regulated genes
2008 Standout
A New Class of Medicines through DNA Editing
2019
A method for characterizing Cas9 variants via a one-million target sequence library of self-targeting sgRNAs
2021
Multiple response elements and differential p53 binding control Perp expression during apoptosis.
2003
Surfing the p53 network
2000 StandoutNature
Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases
2019
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Reversal of DNA alkylation damage by two human dioxygenases
2002 StandoutNobel
MEF immortalization to investigate the ins and outs of mutagenesis
2006
Promotion of direct reprogramming by transformation-deficient Myc
2010 StandoutNobel
Silver-Promoted Desilylation Catalyzed by Ortho- and Allosteric Cucurbiturils
2010
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
2002
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
2003
Works of Alberto Inga being referenced
Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype
2007
Influences of Base Excision Repair Defects on the Lethality and Mutagenicity Induced by Me-lex, a Sequence-selective N3-Adenine Methylating Agent
2002
A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts
2008
Simple identification of dominant p53 mutants by a yeast functional assay
1997
The expanding universe of p53 targets
2009
Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer
1998
A highly specific SpCas9 variant is identified by in vivo screening in yeast
2018
Tumour p53 mutations exhibit promoter selective dominance over wild type p53
2002
p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay
2001
Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma
2000
Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants
2001
Functional Diversity in the Gene Network Controlled by the Master Regulator p53 in Humans
2005
Conserved Pseudoknots in lncRNA MEG3 Are Essential for Stimulation of the p53 Pathway
2019
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements
2001
The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts
2000
Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
2008
Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation
2005
Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence
2002
A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network
2006
Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity
2003
The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes
2006
Mutational fingerprint induced by the antineoplastic drug chloroethyl-cyclohexyl-nitrosourea in mammalian cells.
1995
Mutation spectra analysis suggests that N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea-induced lesions are subject to transcription-coupled repair in Escherichia coli
1997
Functional evolution of the p53 regulatory network through its target response elements
2008
p53 is frequently mutated in Barrett's metaplasia of the intestinal type.
1996
The 5′-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding
2015